Datopotamab Deruxtecan Improves Survival Over Chemotherapy in Patients with Previously Untreated, Locally Recurrent Inoperable or Metastatic TNBC By Ogkologos - April 28, 2026 59 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TROPION-Breast02 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Increasing Education About Cancer Screening and Prevention in Kazakhstan May 11, 2021 ESMO World Congress on Gastrointestinal Cancer 2020 June 22, 2020 Though the Pandemic Has Slowed, Many Are Still Struggling to Put... November 24, 2021 Foster Teen With A Passion For Painting Is Patiently Waiting For... January 30, 2022 Load more HOT NEWS Increased Risk of Haematologic Malignancies Among Children and Adolescents Exposed to... Pembrolizumab Plus Weekly Paclitaxel, With Or Without Bevacizumab, Improves OS in... Five Questions With…Fern, Christina, Mary, and Shelley. Cancer Clinical Trials Bounce Back After Significant COVID-19 Disruption: Data From...
